Intelligent Bio Ownership
INBS Stock | USD 1.39 0.08 6.11% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 1.6 M | Current Value 1.6 M | Avarage Shares Outstanding 1.3 M | Quarterly Volatility 2.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Intelligent |
Intelligent Stock Ownership Analysis
About 14.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.09. Some equities with similar Price to Book (P/B) outperform the market in the long run. Intelligent Bio Solutions recorded a loss per share of 2.3. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 29th of January 2024. GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. Intelligent Bio operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To learn more about Intelligent Bio Solutions call Harry Simeonidis at 646 828 8258 or check out https://ibs.inc.Besides selling stocks to institutional investors, Intelligent Bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Intelligent Bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Intelligent Bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Intelligent Bio Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Intelligent Bio Solutions are currently held by insiders. Unlike Intelligent Bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Intelligent Bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Intelligent Bio's insider trades
Intelligent Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Intelligent Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intelligent Bio Solutions backward and forwards among themselves. Intelligent Bio's institutional investor refers to the entity that pools money to purchase Intelligent Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Hudson Bay Capital Management Lp | 2024-06-30 | 0.0 | Citigroup Inc | 2024-06-30 | 0.0 | Headlands Technologies Llc | 2024-06-30 | 0.0 | Jpmorgan Chase & Co | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Alyeska Investment Group, L.p. | 2024-09-30 | 206.2 K | Cvi Holdings Llc | 2024-06-30 | 79.8 K | Geode Capital Management, Llc | 2024-09-30 | 22.7 K | Vanguard Group Inc | 2024-09-30 | 15.5 K | Adar1 Capital Management Llc | 2024-09-30 | 5.4 K | Ubs Group Ag | 2024-09-30 | 1.6 K |
Intelligent Bio Solutions Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intelligent Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intelligent Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intelligent Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sakiris Spiro Kevin over a month ago Insider Trading | ||
Sakiris Spiro Kevin over six months ago Disposition of 9394 shares by Sakiris Spiro Kevin of Intelligent Bio subject to Rule 16b-3 | ||
Life Science Biosensor Diagnostics Pty Ltd over a year ago Sale by Life Science Biosensor Diagnostics Pty Ltd of 576028 shares of Intelligent Bio | ||
Towers Christopher over a year ago Purchase by Towers Christopher of 9090 shares of Intelligent Bio | ||
Sakiris Spiro Kevin over a year ago Intelligent Bio exotic insider transaction detected | ||
Sakiris Spiro Kevin over a year ago Intelligent Bio exotic insider transaction detected |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Intelligent Stock Analysis
When running Intelligent Bio's price analysis, check to measure Intelligent Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intelligent Bio is operating at the current time. Most of Intelligent Bio's value examination focuses on studying past and present price action to predict the probability of Intelligent Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intelligent Bio's price. Additionally, you may evaluate how the addition of Intelligent Bio to your portfolios can decrease your overall portfolio volatility.